



MedAdvisor Limited
ACN 145 327 617
Level 2, 971 Burke Road
Camberwell Vic 3124
mymedadvisor.com/investors

ASX RELEASE (ASX: MDR)

MedAdvisor expects 1H FY23 revenue to be up 50-60% on 1H FY22

Key highlights:

- **1H FY23 revenue expected to be between \$58 million and \$61 million, up 50-60% on 1H FY22 (\$38.7 million)**
- **As announced on 28 November 2022, the US digital strategy is gaining momentum with the expansion of the COVID-19 awareness program combined with increased pharmacy participation in the US digital platform, inMotion**

Melbourne, Australia, 21 December 2022 - Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) (ASX: MDR) expects 1H FY23 revenue to be between \$58 million and \$61 million, up 50-60% on 1H FY22 (\$38.7 million).

In line with previous announcements, the MedAdvisor US team has accelerated focus on the digitisation of the US pharmacy network and increasing support by major pharmaceutical manufacturers. The momentum behind this strategy going into Q2 is fueling the increased revenue.

With our demonstrated ability to rapidly scale digital programs and show improved patient engagement, additional US pharmacy organizations have recently adopted the MedAdvisor digital platform, inMotion, in Q2. This growth is further underpinned by the typical seasonality of the US business including the extension of the previously announced US COVID-19 awareness program through the end of 2022.

Commenting on the 1H FY23 revenue update, CEO & Managing Director Rick Ratliff, said:

"MedAdvisor is seeing an increase in the use of inMotion thanks to the number of community pharmacies enabling digital access to 60 million individuals combined with MedAdvisor's ability to service this growth at scale through our technology platform.

"The success of our expanded US COVID-19 programs has continued the trend we saw at the end of Q1, and with additional pharmacies participating through inMotion, we are seeing a significant growth in revenue.

As the US deals with health issues related to the flu, RSV and COVID-19, pharmaceutical companies are driving more vaccination awareness and education programs. These programs are to some extent seasonal and we expect to realise the majority of program revenues within this first half.

"We are pleased with the first half revenue momentum, however expect it to moderate in the second half noting the typical seasonal peaks the US business experiences."

- ENDS -

This announcement has been authorised by the Board of MedAdvisor Limited.

For more information please contact:

Company

Ancila Desai

Chief Financial Officer

corporate@medadvisor.com.au

+613 9095 3036

Investors

Ronn Bechler, Automic Markets

ronn.bechler@automicgroup.com.au

+61 400 009 774

Media

Tristan Everett, Automic Markets

tristan.everett@automicgroup.com.au

+61 403 789 096

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 32,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 3.1 million patients through more than 90% of Australian pharmacies. MedAdvisor is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors